Keyphrases
Exenatide Once Weekly
100%
Alcohol Use Disorder
100%
Randomized Placebo-controlled Trial
100%
Exenatide
100%
Receptor Agonist
60%
A1 Receptor
60%
Glucagon-like
60%
Heavy Drinking Days
60%
Functional Magnetic Resonance Imaging
40%
Capital Region
40%
Denmark
40%
Placebo
40%
Treatment Seeking
20%
CT Brain
20%
Hartmann
20%
Placebo-controlled Clinical Trial
20%
Placebo Groups
20%
Brain Regions
20%
Brain Disorders
20%
Drug Addiction
20%
Alcohol Consumption
20%
Lundbeck
20%
Rodents
20%
Novel Therapeutic Targets
20%
Dopamine Transporter
20%
Therapeutic Intervention
20%
Adverse Events
20%
Use Disorder
20%
Single-photon Emission Computed Tomography (SPECT)
20%
Once-weekly
20%
Alcohol Cue Reactivity
20%
Cognitive Behavioral Therapy
20%
Randomized Controlled Trial
20%
Obese Patients
20%
Ventral Striatum
20%
Alcohol Intake
20%
Addiction
20%
Nonhuman Primate
20%
New Targets
20%
Mental Health Services
20%
Septal Area
20%
Drug Reward
20%
Brain Scans
20%
Gastrointestinal
20%
Medicine and Dentistry
Alcoholic Polyneuropathy
100%
Exenatide
100%
Controlled Clinical Trial
100%
Placebo
100%
Glucagon-Like Peptide-1 Agonist
50%
Alcohol Consumption
33%
Addictive Behavior
33%
Functional Magnetic Resonance Imaging
33%
Septal Area
16%
Ventral Striatum
16%
Cue Reactivity
16%
Lomustine
16%
Brain Disease
16%
Cognitive Behavioral Therapy
16%
Mental Health Service
16%
Adverse Event
16%
Randomized Controlled Trial
16%
Brain Scintiscanning
16%
Disease
16%
Brain Areas
16%
Body Mass Index
16%
Dopamine Transporter
16%
Pharmacology, Toxicology and Pharmaceutical Science
Controlled Clinical Trial
100%
Exendin 4
100%
Placebo
100%
Glucagon Like Peptide 1 Receptor Agonist
50%
Ethanol
50%
Disease
16%
Randomized Controlled Trial
16%
Lomustine
16%
Dopamine Transporter
16%
Brain Disease
16%
Adverse Event
16%
